CynapseDx Company

CynapseDx develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from a neurodegenerative disease, such as alzheimer or parkinson disease. They engage in oligomeric and aggregated forms of protein biomarkers and have demonstrated that our assays can measure these forms of biomarker proteins, when testing real patient blood samples.

Headquarters: Liverpool, Liverpool, United Kingdom
Funding Status: Seed
Employee Number: 1-10
Last Funding Type: Seed
Last Funding Date: 08-05-2015
Investors Number: 1
Founded Date: 2010
Industry: NeuroTech